Compass Therapeutics' CTX-8371 Dual PD-1/PD-L1 Bispecific Shows Durable Monotherapy Responses In Advanced Checkpoint-Resistant Cancers With Favorable Safety Profile
Compass Therapeutics Inc. CMPX
$2.20
▲ +6.28%
(+$0.13)
Open
$2.04
Prev Close
$2.07
Day Range
$2.01 – $2.23
52W Range
$1.61 – $6.88
Market Cap
$396.19M
Beta
0.73
EPS (TTM)
$-0.31
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-11-13 |
| Shares Out. | 180,090,000 |
| Website | compasstherapeutics.com/ ↗ |
| Phone | 13026587581 |
Compass Therapeutics Inc. is a publicly traded company under the ticker symbol CMPX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
21 analysts (2026-05-01)